1. PRODUCT NAME

Lithium Carbonate 250mg Capsule.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 250mg of the active substance lithium carbonate.
For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Capsules
Size one capsule with a clear body and a green cap containing white powder.

4. CLINICAL PARTICULARS

4.1. Therapeutic indications

- Treatment of mania and hypomania.
- Treatment of some patients with recurrent bipolar depression, for which treatment with other antidepressants has been unsuccessful.
- Prophylactic treatment of recurrent affective disorders.

4.2. Dose and method of administration

Dose

A simple treatment schedule has been evolved which, except for some minor variations, should be followed whether using Lithium Carbonate therapeutically or prophylactically. The minor variations to this schedule depend on the elements of the illness being treated and these are described later.

1. In patients of average weight (70kg) an initial dose of 400-1,200mg of Lithium Carbonate may be given as a single daily dose in the morning or on retiring. Alternatively, the dose may be divided and given morning and evening. When changing from other lithium preparations serum lithium levels should first be checked, then Lithium Carbonate therapy commenced at a daily dose as close as possible to the dose of the other form of lithium. As bioavailability varies from product to product (particularly with regard to retard or slow release preparations), a change of product should be regarded as initiation of new treatment.
2. Four to five days after starting treatment (and never longer than one week) a blood sample should be taken for the estimation of serum lithium level.

3. The objective is to adjust the Lithium carbonate dose so as to maintain the serum lithium level permanently within the diurnal range of 0.5 – 1.5 mmol/L. In practice, the blood sample should be taken between 12 and 24 hours after the previous dose of Lithium carbonate. ‘Target’ serum lithium concentrations at 12 and 24 hours are shown in Table 1. Serum lithium levels should be monitored weekly until stabilisation is achieved.

Table 1: ‘Target’ serum lithium concentrations (mmol/L)

<table>
<thead>
<tr>
<th></th>
<th>At 12 hours</th>
<th>At 24 hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Once daily dosage</td>
<td>0.7 – 1.0</td>
<td>0.5 – 0.8</td>
</tr>
<tr>
<td>Twice daily dosage</td>
<td>0.5 – 0.8</td>
<td></td>
</tr>
</tbody>
</table>

4. Lithium therapy should not be initiated unless adequate facilities for routine monitoring of serum concentrations are available. Following stabilisation of serum lithium levels, the period between subsequent estimations can be increased gradually but should not normally exceed three months. Additional measurements should be made following alteration of dosage, on development of intercurrent disease, signs of manic or depressive relapse, following significant change in sodium or fluid intake, or if signs of lithium toxicity occur.

5. Whilst a high proportion of acutely ill patients may respond within three to seven days of the commencement of Lithium carbonate therapy, Lithium carbonate should be continued through any recurrence of the affective disturbance. This is important as the full prophylactic effect may not occur for 6 to 12 months after the initiation of therapy.

6. In patients who show a positive response to Lithium Carbonate therapy, treatment is likely to be long term. Careful clinical appraisal of the patient should be exercised throughout medication (see section 6.6 Special precautions for disposal and other handling).

**Treatment of Acute Mania, Hypomania and Recurrent Bipolar Depression:**

It is likely that a higher than normal Lithium Carbonate intake may be necessary during an acute phase and divided doses would be required here. Therefore, as soon as control of mania or depression is achieved, the serum lithium level should be determined and it may be necessary, dependent on the results, to lower the dose of...
Lithium Carbonate and re-stabilise serum lithium levels. In all other details the described treatment schedule is recommended.

**Prophylactic Treatment of Recurrent Affective Disorders:**

It is recommended that the described treatment schedule is followed.

**Elderly population**

In elderly patients or those below 50kg in weight, it is recommended that the starting dose be 400mg. Elderly patients may be more sensitive to undesirable effects of lithium and may also require lower doses in order to maintain normal serum lithium levels. It follows therefore that long term patients often require a reduction in dosage over a period of years.

**Children and Adolescents:**

Not recommended.

**Renal impairment:**

Lithium is contraindicated in patients with significant renal disease *(see Section 4.3 Contraindications)*.

**Method of Administration**

Lithium should be taken with food, as it causes less nausea than on an empty stomach.

**4.3. Contraindications**

- Patients with significant cardiovascular disease.
- Patients with significant renal disease
- Untreated hypothyroidism.
- Conditions associated with hyponatremia, for example: Addison’s disease, dehydrated or severely debilitated patients, patients on low sodium diets.
- Diuretics should not be used during lithium therapy without appropriate dosage adjustment.
- Hypersensitivity to lithium or any of the excipients contained in the capsule.
- Breastfeeding

**4.4. Special warnings and precautions for use**

- **General:**
  When considering lithium therapy, it is necessary to ascertain whether patients are receiving lithium in any other form. If so, check serum levels before proceeding.
Patients receiving lithium therapy should be taught to recognise the symptoms of early toxicity and, should these occur, to discontinue therapy and request medical aid at once (see section 4.9).

Lithium toxicity is closely related to serum lithium concentrations and can occur at doses close to therapeutic concentrations. For monitoring recommendations of lithium serum levels see Section 4.2.

- **Monitoring recommendations**
  - **Pre-treatment**
    Physical examination and laboratory testing are required prior to commencement of therapy, and should be repeated at frequent intervals.

   Since lithium is excreted primarily by the kidney, adequate renal function is essential in order to avoid lithium accumulation and intoxication. If necessary, a creatinine clearance test or other renal function test should be performed.

   Cardiac, thyroid and parathyroid (parathyroid hormone and serum calcium level) function should be assessed before commencing lithium treatment. Thus, a decision to initiate lithium therapy should be preceded by a thorough clinical examination and evaluation of each patient, including laboratory determinations, ECG, and a very careful assessment of renal function.

- **On treatment**
  Patients receiving lithium should be examined periodically for abnormal thyroid and parathyroid function (see section 4.4 - Hypercalcaemia and Hyperparathyroidism), since goitre and hypothyroidism may develop. Cardiac and renal function should be monitored regularly. Care should be taken in the presence of encephalopathy syndrome or intercurrent infection.

  Patients should be maintained under careful clinical and laboratory control throughout treatment. Means of obtaining accurate determination of serum lithium levels should be available since frequent serum determinations are required during the initial period of treatment.

- **Renal impairment**
  Chronic lithium therapy may be associated with diminution of renal concentrating ability, occasionally presenting as nephrogenic diabetes insipidus with polyuria and polydipsia. Such patients should be carefully managed to avoid
dehydration with resulting lithium retention and toxicity. This condition is usually reversible when lithium is discontinued. Morphologic changes with glomerular and interstitial fibrosis and nephron atrophy have also been reported in patients on chronic lithium therapy. Some structural changes have also been reported in manic-depressives never exposed to lithium. The relationship between renal function, morphologic changes and lithium therapy has not been established. When kidney function is assessed, routine urinalysis and other tests may be used to evaluate tubular function (eg urine specific gravity, osmolality following water deprivation or 24 hour urine volume) and glomerular function (e.g. serum creatinine or creatinine clearance). Of note, acute renal failure has been reported rarely with lithium toxicity.

- **Fluid/electrolyte balance:**
  Vomiting, diarrhoea, intercurrent infection, fluid deprivation and drugs likely to upset electrolyte balance, such as diuretics, may all reduce lithium excretion thereby precipitating intoxication. Therefore, reduction in the dosage of lithium may be required. Lithium requirements may change during fever, infection, and when mood swings occur. Patients in a manic state seem to have increased tolerance to lithium which decreases when manic symptoms subside.

  Patients should avoid low-salt dietary regimens or other dietary changes which may reduce sodium intake, or circumstances which may cause excessive sodium loss such as heavy exercise leading to excessive sweating as these may lead to increased lithium concentrations.

  The patient, therefore, should maintain a normal diet with adequate salt and fluid intake during therapy.

- **Hypercalcaemia and Hyperparathyroidism:**
  Systematic review indicates that about 10 % of patients taking lithium long-term develop hypercalcaemia with or without hyperparathyroidism. Patients should be checked for parathyroid function prior to commencing treatment.

  Serum calcium levels should be monitored at least yearly in all patients taking lithium. Monitoring should be more frequent if an abnormal result is found or the patient has a family history of endocrine disease. If serum calcium levels are raised the serum parathyroid level should be measured. If both parathyroid hormone levels and calcium levels are elevated the patient should be referred for specialist treatment.
In cases of mild hypercalcaemia with normal parathyroid hormone levels, treatment may be continued if the benefits are considered to outweigh the risks, but calcium levels should be monitored more frequently.

If serum calcium levels rise above 11 mg/dL, lithium treatment should be stopped and calcium levels measured weekly for the next 4 weeks to ensure that levels drop back to normal.

Patients who have undergone parathyroidectomy in the past may experience recurrent hyperparathyroidism on lithium treatment; serum calcium and parathyroid hormone levels should be carefully monitored.

- **Electroconvulsive therapy:**
  Lithium should be temporarily discontinued before electroconvulsive therapy (ECT) to reduce the risk of delirium, which may occur when the two treatments are co-administered.

- **Surgery:**
  It is wise to discontinue lithium for 24 hours before any major operation. Provided serum electrolytes are in balance it can, and normally should, be restarted soon after the operation. Complete discontinuation of prophylactic lithium therapy should be discussed between patient, general practitioner and specialist.

- **Children:**
  Information regarding the safety and efficacy in children under 12 years of age is not available, therefore lithium therapy is not recommended in this age group.

- **Elderly patients:**
  Lithium should be used with care in the elderly as excretion may be reduced, resulting in a longer half-life. The elderly may, therefore exhibit signs of toxicity at serum concentrations ordinarily tolerated by younger patients. Elderly patients also often require lower lithium dosages to achieve therapeutic serum concentrations.

**4.5. Interaction with other medicines and other forms of interaction**

If one of the following medicines is initiated, regular monitoring of serum lithium levels and for signs of lithium toxicity should be performed during concomitant treatment. Lithium dosage should either be adjusted or concomitant treatment stopped, as appropriate.
Interactions that may increase lithium concentrations:
- Selective Serotonin Re-uptake Inhibitors (SSRIs)
- Metronidazole
- Tetracyclines
- Topiramate
- Non-steroidal anti-inflammatory drugs (NSAID)
- ACE inhibitors
- Thiazide diuretics (may cause a paradoxical antidiuretic effect resulting in possible water retention and lithium intoxication)
- Spironolactone
- Frusemide
- Angiotensin-II receptor antagonists
- Other drugs affecting electrolyte balance may alter lithium excretion, e.g. steroids

Interactions that may decrease lithium concentrations:
- Xanthines (theophylline, caffeine)
- Sodium bicarbonate and Sodium Chloride containing products
- Psyllium or Ispaghula husk
- Urea
- Mannitol
- Acetazolamide

Interactions that may cause neurotoxicity:
- Neuroleptics (risperidone, clozapine, phenothiazines, and particularly haloperidol) may lead to, in rare cases, neurotoxicity in the form of an encephalopathic syndrome, characterised by weakness, lethargy, fever, tremulousness, confusion, extrapyramidal symptoms and leucocytosis. In some instances, the syndrome was followed by irreversible brain damage. Because there is a possible causal relationship between these events and treatment with lithium and neuroleptics, patients receiving combined therapy should be monitored closely for early evidence of neurological toxicity and treatment discontinued promptly if symptoms appear. This encephalopathic syndrome may be similar to or the same as neuroleptic malignant syndrome.
- SSRIs, Sumitriptan and Tricyclic Antidepressants have been associated with episodes of neurotoxicity, and may precipitate a serotoninergic syndrome - either event justifies immediate discontinuation of treatment.
- Calcium channel blockers may lead to a risk of neurotoxicity in the form of ataxia, confusion and somnolence, reversible after discontinuation of the drug. Lithium concentrations may be increased or decreased.
• Carbamazepine or phenytoin may lead to dizziness, somnolence, confusion and cerebellar symptoms.
• Methylldopa

Other interactions:
• Lithium may prolong the effects of neuromuscular blocking agents
• Thioridazine may increase risk of ventricular dysrhythmias
• Iodide and lithium may act synergistically to produce hypothyroidism
• There have also been case reports of lithium interactions with baclofen, co-trimoxazole, aciclovir and prostaglandin-synthetase inhibitors. The clinical significance of these interactions is uncertain.

4.6. Fertility, pregnancy and lactation

Pregnancy
There is epidemiological evidence that lithium may be harmful to the foetus in human pregnancy.

<table>
<thead>
<tr>
<th>Total no. “lithium babies” reported</th>
<th>Malformed infants</th>
<th>Ebstein’s anomaly and other major cardiovascular malformations</th>
</tr>
</thead>
<tbody>
<tr>
<td>225</td>
<td>25 (11%)</td>
<td>18 (8%)</td>
</tr>
</tbody>
</table>

It is strongly recommended that lithium be discontinued before a planned pregnancy. If it is considered essential to maintain Lithium Carbonate treatment during pregnancy, serum lithium levels should be monitored closely since renal function changes gradually during pregnancy and suddenly at parturition, requiring dosage adjustments. It is recommended that lithium be discontinued shortly before delivery and recommenced a few days post-partum.

Breast-feeding
Lithium is able to cross the placenta and is excreted in breast milk. Babies may show signs of lithium toxicity necessitating fluid therapy in the neonatal period. Babies born with low serum lithium concentrations may have a flaccid appearance which returns to normal without any treatment. Therefore bottle feeding is recommended.

4.7. Effects ability to drive and use machines
Lithium may cause disturbances of the central nervous system (eg somnolence, dizziness, and hallucinations). Furthermore at the beginning of treatment the occasional onset of fatigue can impair reflexes. Therefore, Impaired driving performance or machine operation skills may occur in patients receiving lithium.
4.8. Undesirable effects

The occurrence and severity of adverse reactions are generally directly related to
serum lithium concentrations as well as to individual sensitivity to lithium and
generally occur more frequently and with greater severity at higher concentrations.

The most frequent adverse effects are the initial post-absorptive symptoms,
believed to be associated with a rapid rise in serum lithium levels. They include
gastrointestinal discomfort with mild nausea and diarrhoea, vertigo, muscle
weakness and a dazed feeling and frequently disappear after stabilisation of
therapy.

The more common and persistent adverse reactions are: fine tremor of the hands,
fatigue, thirst and polyuria. These do not necessarily require reduction of dosage.
Nausea is usually transient

Adverse effects occurring at therapeutic serum lithium concentrations include
anorexia, constipation or diarrhoea, epigastric discomfort, metallic taste, headache,
vertigo, fine tremor, polyuria with polydipsia, and oedema. Hypercalcaemia has
been reported in about 10% of patients taking lithium, hypermagnesaemia and
hyperparathyroidism have also been reported. Reversible ECG changes e.g. T wave
flattening or inversion, cardiac arrhythmias and EEG changes have been reported.
Exacerbation of skin conditions (such as acne and psoriasis) and leucocytosis are
relatively common side-effects of lithium therapy. Significant weight gain is also
observed in many patients receiving lithium.

Long term administration of lithium carbonate may precipitate goitre requiring
treatment with thyroxine, but this regresses when treatment is discontinued. Hair
thinning and mild cognitive impairment may occur. Rarely hyperthyroidism,
hyperparathyroidism and nephrogenic diabetes insipidus have been reported.

Toxic effects may be expected at serum-lithium concentrations over 1.5 mmol/L,
although they can appear at lower concentrations. They call for immediate
withdrawal of treatment and should always be considered very seriously. Signs of
toxicity include increasing diarrhoea, vomiting, anorexia, severe abdominal
discomfort, polyuria, muscle weakness, lethargy, ataxia, lack of co-ordination,
tinnitus, blurred vision, dry mouth, dysgeusia and impotence/sexual dysfunction,
coarse tremor (marked) of the extremities and lower jaw, muscle hyperirritability
and twitching, agitation, hyper-reflexia, choreoathetoid movements, dysarthria,
disorientation, psychosis, drowsiness, seizures and coma. At higher concentrations,
ataxia, tinnitus, blurred vision, giddiness and increasing polyuria are seen.
The following reactions appear to be related to serum lithium concentrations. Adverse reactions can occur in patients with serum concentrations within the therapeutic range (i.e. below 1.5 mmol/L or lower in the elderly).

- Body as a whole: Oedema
- Cardiovascular: Arrhythmia, hypotension, ECG changes including non-specific T wave changes, oedema, Raynaud’s phenomena, peripheral circulatory collapse, bradycardia, sinus node dysfunction.
- Dermatological: Alopecia, acne, folliculitis, pruritus, psoriasis exacerbation, rash.
- Endocrine: Euthyroid goitre, hypothyroidism, rare cases of hyperthyroidism, hyperglycaemia, hypercalcaemia, hypermagnesemia, hyperparathyroidism.
- Gastrointestinal: Anorexia, nausea, vomiting, diarrhoea, constipation, gastritis, excessive salivation, abdominal pain.
- Haematological: Leucocytosis.
- Hypersensitivity: Angioedema.
- Neuromuscular/CNS: Tremor, fasciculations, twitching clonic movements of extremities, ataxia, choreoathetoid movements, hyperactive deep tendon reflexes, extrapyramidal symptoms, syncope, seizures, slurred speech, dizziness, vertigo, nystagmus, somnolence, stupor, coma, hallucinations, taste distortion, taste impairment, scotomata, pseudotumour cerebri, autonomic effects including blurred vision, dry mouth, impotence/sexual dysfunction, headache and EEG changes. Myasthenia gravis has been observed rarely.
- Renal: Symptoms of nephrogenic diabetes insipidus.

It is vital to bear in mind that lithium can be lethal, if prescribed or ingested in excess.

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected reactions [https://nzphvc.otago.ac.nz/reporting/](https://nzphvc.otago.ac.nz/reporting/)

4.9. Overdose

**Symptoms**

In acute overdose, vomiting often occurs within an hour of ingestion due to the high concentration of lithium in the stomach, but significant amounts of lithium can still reach the systemic circulation. The typical clinical symptoms often appear after a
latency period and gastrointestinal symptoms can re-appear at a later time. The symptoms of overdose are reported to be mainly related to the alimentary and nervous systems and include abdominal pain, anorexia, nausea, vomiting, occasionally mild diarrhoea, giddiness, tremor, ataxia, slurring speech, myoclonus, twitching, asthenia, depression, renal symptoms.

Coma and convulsions may occur in serious cases and cardiac effects (first-degree heart block and QRS and QT prolongation) have been described rarely. A patient may appear to be aware with open eyes but have an expressionless face and be unable to move or speak (coma vigil). Acute renal failure and nephrogenic diabetes insipidus may develop.

**Treatment**

Treatment is symptomatic and supportive; close monitoring of vital signs is recommended. Activated charcoal is of no value as it does not adsorb lithium. Whole bowel irrigation has been suggested, however, there are no clinical studies to confirm efficacy.

Further measures may involve procedures to enhance the renal clearance of lithium or its active removal. Adequate hydration should be ensured and any electrolyte imbalance corrected, but forced diuresis or diuretics should not be used (*see Section 4.5*). Appropriate supportive care may include measures to control hypotension and convulsions. Maintenance of fluid and electrolyte balance is particularly important because of the risk of hypernatraemia. The ECG should be monitored in symptomatic patients.

In severe poisoning, haemodialysis is the treatment of choice (particularly if there is renal impairment). Although effective in reducing serum-lithium concentrations, substantial rebound increases can be expected when dialysis is stopped, and prolonged or repeated treatments may be required. Peritoneal dialysis is less effective and only appropriate if haemodialysis facilities are not available. Haemofiltration has been tried to good effect.

Serum lithium concentrations should be monitored regularly throughout treatment. Once the serum and dialysis fluid are free of lithium, it has been recommended that serum-lithium concentrations should be monitored for at least another week so that allowance can be made for delayed diffusion from body tissues.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).
5. PHARMACOLOGICAL PROPERTIES

5.1. Pharmacodynamic properties

Pharmacotherapeutic Group: Psycholeptics; Antipsychotics; Lithium
ATC code: N05AN01
Mechanism of action
Lithium Carbonate provides a source of lithium ions that may act by competing with sodium ions at various sites in the body. Therapeutic concentrations of lithium have almost no discernible psychotropic effects in normal volunteers but considerable effect in patients suffering from affective disorders. The mechanism of action is unknown.

5.2. Pharmacokinetic properties

Absorption:
Lithium ions are almost completely absorbed from the gastrointestinal tract, complete absorption occurring after about 8 hours. Peak plasma concentrations occur after about 2-4 hours.

Distribution:
Lithium initially distributes into extracellular fluid and then to most other tissues. The final volume of distribution equals that of total body water. Lithium slowly enters cerebrospinal fluid achieving at steady state 40% of the plasma concentration. Lithium is able to cross the placenta and is excreted in breast milk.

Elimination:
Occurs via the kidneys but lithium can also be detected in sweat and saliva. The biological half-life is variable ranging from 7-20 hours and may be longer at night. Poor renal function impairs excretion.

Special Population
Elimination half-life may be increased in elderly patients due to age related decrease in renal function and also in patients with renal impairment (see Sections 4.2 and 4.4).

5.3. Preclinical safety data

In animal studies, lithium has been reported to interfere with fertility, gestation and foetal development.
6. PHARMACEUTICAL PARTICULARS

6.1. List of excipients
- Lactose monohydrate
- Maize starch
- Magnesium stearate
- Gelatin
- EEC Quinoline Yellow E104
- FD&C Blue #1 E133
- FD&C Yellow #6 E110

6.2. Incompatibilities
- Not applicable

6.3. Shelf life
- 3 years

6.4. Special precautions for storage
- Below 30°C. Store in the original packaging in order to protect from light and moisture.

6.5. Nature and contents of container
- Lithium Carbonate 250mg capsule
- HDPE Plastic bottles of 100

6.6. Special precautions for disposal and other handling
- No special requirements

7. MEDICINE SCHEDULE
- Prescription Medicine.

8. SPONSOR
- Douglas Pharmaceuticals Ltd
  P O Box 45 027
  Auckland 0651
  New Zealand
  Phone: (09) 835 0660
  Fax: (09) 835 0665

9. DATE OF FIRST APPROVAL
- 08 November 1985
## Summary table of changes

<table>
<thead>
<tr>
<th>Section Changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.3</td>
<td>New bullet point: patients with significant renal disease</td>
</tr>
<tr>
<td>5.1</td>
<td>Pharmacotherapeutic Group and ATC code added</td>
</tr>
<tr>
<td>5.2</td>
<td>New section added: Special population</td>
</tr>
<tr>
<td>6.1</td>
<td>Addition of the following: Gelatin, EEC Quinoline, Yellow E104, FD&amp;C Blue #1 E133, FD&amp;C Yellow #6 E110</td>
</tr>
<tr>
<td>6.4</td>
<td>Omitted: blister</td>
</tr>
<tr>
<td>6.5</td>
<td>Added: HDPE Plastic bottles</td>
</tr>
</tbody>
</table>